🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementFAERS pharmacovigilance data for semaglutide — anyone have experience? Page 7

FAERS pharmacovigilance data for semaglutide — anyone have experience?

bri_stats Thu, Mar 21, 2024 at 2:29 PM 36 replies 2,800 viewsPage 7 of 8
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Apr 24, 2024 at 8:03 AM#31
DanielChem_CHI said:
Worth stating the units and the reference range whenever you post a number here.

Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.

39 12Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 36 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Apr 26, 2024 at 11:58 AM#32
DanielChem_CHI said:
Worth stating the units and the reference range whenever you post a number here.

That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.

Last edited: Apr 26, 2024 at 2:58 PM
40 13laura_annarbor, JenMemphis, pat_auckland and 37 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Apr 28, 2024 at 3:52 PM#33

Clinical perspective, offered as context rather than as advice. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

41 14adam_van, Dr.SurgeonPGH, rachel_ABQ and 38 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NauseaFreeNow
Member
345
1,234
Aug 2024
Indiana
Apr 30, 2024 at 7:45 PM#34
paige_pharma said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

This is my experience too, for whatever a second data point is worth.

Last edited: Apr 30, 2024 at 11:45 PM
42 15lori_vegas, Dr.PulmRoch, maya_sedona and 39 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
May 2, 2024 at 11:37 PM#35
paige_pharma said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

There is a second half to this that has not been said yet. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

43 16TirzTom, TrialTracker_MD, JennaRN and 40 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register